skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Duncan


21+ years of experience

Duncan Emerton Pharma Intelligence
Highly experienced pharma, biotech and consulting professional gained from roles in non-clinical and clinical R&D, sales, marketing, medical affairs, management consulting, and business analysis.

Duncan has over 20 years of pharmaceutical industry experience and is currently Director of Informa Pharma’s Custom Intelligence & Analytics team which focuses on supporting pharma, biotech, and life science clients to make informed decisions across the clinical-regulatory-commercial continuum.

Previously worked for a global market research firm where he was responsible for all syndicated disease analysis. Prior to that spent nearly a decade at Datamonitor Healthcare where he worked in company analysis, disease analysis, and the healthcare consulting team. Duncan has also held various roles at several pharma companies focused on non-clinical and clinical R&D, medical affairs, and sales/marketing.

A published authority on biosimilars, COVID-19 and lifecycle management, having authored whitepapers, articles and book chapters on these areas, including two chapters in Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand (Wiley, 2012).

Duncan holds a BSc(Hons) in Biochemistry from the University of Surrey and a PhD in Microbiology from the University of Kent.

Analyst Articles

Articles by Duncan

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Pharma R&D’s COVID-19 Scar

    By Duncan Emerton 26 Nov 2020

    Pharma R&D’s COVID-19 Scar

    Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

    Topic Coronavirus research